The Important Role of T Cells and Receptor Expression in Sjögren's Syndrome

Scandinavian Journal of Immunology

Volumn 78, Issue 2, 2013, Pages 157-166

  Karabiyik, A ^a   Peck, A B ^a,b   Nguyen, C Q ^a,b  

^a University of Florida College of Veterinary Medicine   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; EXOCRINE GLAND; HELPER CELL; HUMAN; HYPERSENSITIVITY; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; AUTOANTIGENS; B-LYMPHOCYTES; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; EXOCRINE GLANDS; GENE EXPRESSION; HUMANS; MICE; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84880658498     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12079     Document Type: Review

References (105)

1. Fox RI, Kang HI. Pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am 1992;18:517-38.
2. Fox RI, Michelson P. Approaches to the treatment of Sjogren's syndrome. J Rheumatol Suppl 2000;61:15-21.
3. Liew MS, Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjogren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol 2012;96:1498-503.
4. Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
5. Sullivan DA. Androgen deficiency & dry eye syndromes. Arch Soc Esp Oftalmol 2004;79:49-50.
6. Toda I, Wickham LA, Sullivan DA. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. Clin Immunol Immunopathol 1998;86:59-71.
7. Sullivan DA. Sex hormones and Sjogren's syndrome. J Rheumatol Suppl 1997;50:17-32.
8. Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul Surf 2009;7:11-27.
9. Ambrosetti A, Zanotti R, Pattaro C et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 2004;126:43-9.
10. De Vita S, Boiocchi M, Sorrentino D et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum 1997;40:318-31.
11. Ramos-Casals M, Trejo O, Garcia-Carrasco M et al. Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004;31:495-9.
12. Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep 2003;5:317-23.
13. Lin DF, Yan SM, Zhao Y et al. Clinical and prognostic characteristics of 573 cases of primary Sjogren's syndrome. Chin Med J (Engl) 2010;123:3252-7.
14. Nguyen CQ, Cha SR, Peck AB. Sjogren's syndrome (SjS)-like disease of mice: the importance of B lymphocytes and autoantibodies. Front Biosci 2007a;12:1767-89.
15. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43.
16. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181:2898-906.
17. Peck AB, Nguyen CQ, Sharma A, McIndoe RA, She JX. The interferon-signature of Sjögren's syndrome: what does it say about the etiopathology of autoimmunity. J Clinical Rheum & Musculoskeletal Med 2011;1:1-17.
18. Peck AB, Nguyen CQ. Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjogren's syndrome. Scand J Immunol 2012;76:237-45.
19. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001;114:4143-51.
20. Kong L, Robinson CP, Peck AB et al. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol 1998;16:675-81.
21. Brayer JB, Cha S, Nagashima H et al. IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjogren's syndrome. Scand J Immunol 2001;54:133-40.
22. Nguyen KH, Brayer J, Cha S et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice. Arthritis Rheum 2000a;43:2297-306.
23. Abdul Ajees A, Gunasekaran K, Volanakis JE, Narayana SV, Kotwal GJ, Murthy HM. The structure of complement C3b provides insights into complement activation and regulation. Nature 2006;444:221-5.
24. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
25. Batten M, Fletcher C, Ng LG et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004;172:812-22.
26. Nguyen CQ, Sharma A, Lee BH, She JX, McIndoe RA, Peck AB. Differential gene expression in the salivary gland during development and onset of xerostomia in Sjogren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Arthritis Res Ther 2009;11:R56.
27. Okuma A, Hoshino K, Ohba T et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces sjogren's syndrome-like autoimmune disease. Immunity 2013;38:450-60.
28. Bombardieri M, Barone F, Pittoni V et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004;6:R447-56.
29. Manoussakis MN, Boiu S, Korkolopoulou P et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007;56:3977-88.
30. Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjogren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther 2008;10:R22.
31. Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun 2006;26:90-103.
32. Gao J. Biological Functions and Molecular Mechanisms of the Interleukin 4 Signaling Pathways in Autoimmune Exocrinopathy Using the NOD.B10.H2b Mouse Model of Sjögren's Syndrome. Gainesville, FL: University of Florida, 2004. UFE0006639:00001.
33. Nguyen CQ, Gao JH, Kim H, Saban DR, Cornelius JG, Peck AB. IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjogren's syndrome-like disease of the nonobese diabetic mouse. J Immunol 2007b;179:382-90.
34. Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sjogren's syndrome. J Rheumatol 2007;34:2044-9.
35. Salomonsson S, Jonsson MV, Skarstein K et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003;48:3187-201.
36. Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA. Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome. Rheumatology 2009;48:1102-6.
37. Szodoray P, Alex P, Jonsson MV et al. Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005;117:168-76.
38. Reksten TR, Johnsen SJ, Jonsson MV et al. Genetic associations to germinal centre formation in primary Sjogren's syndrome. Ann Rheum Dis 2013.
39. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005;5:853-65.
40. Maehara T, Moriyama M, Hayashida JN et al. Selective localization of T helper subsets in labial salivary glands from primary Sjogren's syndrome patients. Clin Exp Immunol 2012a;169:89-99.
41. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32.
42. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
43. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89.
44. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
45. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231-4.
46. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005;5:521-31.
47. Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-33.
48. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9:641-9.
49. Schraml BU, Hildner K, Ise W et al. The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature 2009;460:405-9.
50. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52.
51. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42.
52. Bikker A, van Woerkom JM, Kruize AA et al. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjogren's syndrome correlates with increased inflammation. Arthritis Rheum 2010;62:969-77.
53. Bikker A, Moret FM, Kruize AA, Bijlsma JW, Lafeber FP, van Roon JA. IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in CD4 T cells lacking the IL-7Ralpha. Rheumatology 2012;51:996-1005.
54. Jin J-O, Kawai T, Cha S, Yu Q. Interleukin-7 enhances Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy. Arthritis Rheum 2013.
55. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-7.
56. Huber M, Brustle A, Reinhard K et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci U S A 2008;105:20846-51.
57. Chen Q, Yang W, Gupta S et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008;29:899-911.
58. Kuchen S, Robbins R, Sims GP et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007;179:5886-96.
59. Pene J, Gauchat JF, Lecart S et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol 2004;172:5154-7.
60. Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004;50:2615-21.
61. Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. IL17: potential therapeutic target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011;91:54-62.
62. Maehara T, Moriyama M, Nakashima H et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Ann Rheum Dis 2012b;71:2011-9.
63. Kang KY, Kim HO, Kwok SK et al. Impact of interleukin-21 in the pathogenesis of primary Sjogren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011;13:R179.
64. McGuire HM, Vogelzang A, Ma CS et al. A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity 2011;34:602-15.
65. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009;31:15-23.
66. Ciccia F, Guggino G, Rizzo A et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012;71:295-301.
67. Lavoie TN, Stewart CM, Berg KM, Li Y, Nguyen CQ. Expression of interleukin-22 in Sjogren's syndrome: significant correlation with disease parameters. Scand J Immunol 2011;74:377-82.
68. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008;22:1595-603.
69. Gelebart P, Zak Z, Dien-Bard J, Anand M, Lai R. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011;4:9-19.
70. Miyagaki T, Sugaya M, Suga H et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 2011;17:7529-38.
71. Ciccia F, Giardina A, Rizzo A et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis 2013;72:782-3.
72. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002;109 (Suppl):S45-55.
73. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334:395-402.
74. Garcia KC, Adams EJ. How the T cell receptor sees antigen - a structural view. Cell 2005;122:333-6.
75. Hodges E, Krishna MT, Pickard C, Smith JL. Diagnostic role of tests for T cell receptor (TCR) genes. J Clin Pathol 2003;56:1-11.
76. Rabbitts TH, Lefranc MP, Stinson MA et al. The chromosomal location of T-cell receptor genes and a T cell rearranging gene: possible correlation with specific translocations in human T cell leukaemia. EMBO J 1985;4:1461-5.
77. Roman-Roman S, Ferradini L, Azocar J, Genevee C, Hercend T, Triebel F. Studies on the human T cell receptor alpha/beta variable region genes. I. Identification of 7 additional V alpha subfamilies and 14 J alpha gene segments. Eur J Immunol 1991;21:927-33.
78. Huang CY, Sleckman BP, Kanagawa O. Revision of T cell receptor alpha chain genes is required for normal T lymphocyte development. Proc Natl Acad Sci USA 2005;102:14356-61.
79. Bosc N, Lefranc MP. The mouse (Mus musculus) T cell receptor alpha (TRA) and delta (TRD) variable genes. Dev Comp Immunol 2003;27:465-97.
80. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996;272:1755-62.
81. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995a;42:455-500.
82. Toyonaga B, Mak TW. Genes of the T-cell antigen receptor in normal and malignant T cells. Annu Rev Immunol 1987;5:585-620.
83. Boria I, Cotella D, Dianzani I, Santoro C, Sblattero D. Primer sets for cloning the human repertoire of T cell Receptor Variable regions. BMC Immunol 2008;9:50.
84. Lefranc MP, Giudicelli V, Ginestoux C et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2009;37:D1006-12.
85. Lee YN, Alt FW, Reyes J, Gleason M, Zarrin AA, Jung D. Differential utilization of T cell receptor TCR alpha/TCR delta locus variable region gene segments is mediated by accessibility. Proc Natl Acad Sci USA 2009;106:17487-92.
86. Murphy K. Janeway's Immunobiology. 8th edn. UK: Taylor and Francs, 2011. ISBN:9780815342434.
87. Arden B, Clark SP, Kabelitz D, Mak TW. Mouse T-cell receptor variable gene segment families. Immunogenetics 1995b;42:501-30.
88. Alt FW, Oltz EM, Young F, Gorman J, Taccioli G, Chen J. VDJ recombination. Immunol Today 1992;13:306-14.
89. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999;286:958-61.
90. Davis MM, Boniface JJ, Reich Z et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 1998;16:523-44.
91. Wang GC, Dash P, McCullers JA, Doherty PC, Thomas PG. T cell receptor alphabeta diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med 2012;4:128ra42.
92. Jung D, Alt FW. Unraveling V(D)J recombination; insights into gene regulation. Cell 2004;116:299-311.
93. Gellert M. Molecular analysis of V(D)J recombination. Annu Rev Genet 1992;26:425-46.
94. Zumla A, Mathur M, Stewart J, Wilkinson L, Isenberg D. T cell receptor expression in Sjogren's syndrome. Ann Rheum Dis 1991;50:691-3.
95. Sumida T, Kita Y, Yonaha F, Maeda T, Iwamoto I, Yoshida S. T cell receptor V alpha repertoire of infiltrating T cells in labial salivary glands from patients with Sjogren's syndrome. Journal Rheumatol 1994a;21:1655-61.
96. Sumida T, Matsumoto I, Maeda T, Nishioka K. T-cell receptor in Sjogren's syndrome. Br J Rheumatol 1997;36:622-9.
97. Sumida T, Sakamaki T, Yonaha F et al. HLA-DR alleles in patients with Sjogren's syndrome over-representing V beta 2 and V beta 13 genes in the labial salivary glands. Br J Rheumatol 1994b;33:420-4.
98. Skarstein K, Wahren M, Zaura E, Hattori M, Jonsson R. Characterization of T cell receptor repertoire and anti-Ro/SSA autoantibodies in relation to sialadenitis of NOD mice. Autoimmunity 1995;22:9-16.
99. Hayashi Y, Hamano H, Haneji N, Ishimaru N, Yanagi K. Biased T cell receptor V beta gene usage during specific stages of the development of autoimmune sialadenitis in the MRL/lpr mouse model of Sjogren's syndrome. Arthritis Rheum 1995;38:1077-84.
100. Legras F, Martin T, Knapp AM, Pasquali JL. Infiltrating T cells from patients with primary Sjogren's syndrome express restricted or unrestricted T cell receptor V beta regions depending on the stage of the disease. Eur J Immunol 1994;24:181-5.
101. Dwyer E, Itescu S, Winchester R. Characterization of the primary structure of T cell receptor beta chains in cells infiltrating the salivary gland in the sicca syndrome of HIV-1 infection. Evidence of antigen-driven clonal selection suggested by restricted combinations of V beta J beta gene segment usage and shared somatically encoded amino acid residues. J Clin Invest 1993;92:495-502.
102. Smith MD, Lamour A, Boylston A et al. Selective expression of V beta families by T cells in the blood and salivary gland infiltrate of patients with primary Sjogren's syndrome. Journal Rheumatol 1994;21:1832-7.
103. Mizushima N, Kohsaka H, Tsubota K, Saito I, Miyasaka N. Diverse T cell receptor beta gene usage by infiltrating T cells in the lacrimal glands of Sjogren's syndrome. Clin Exp Immunol 1995;101:33-8.
104. Matsumoto I, Tsubota K, Satake Y et al. Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjogren's syndrome. J Clin Invest 1996;97:1969-77.
105. Murata H, Kita Y, Sakamoto A et al. Limited TCR repertoire of infiltrating T cells in the kidneys of Sjogren's syndrome patients with interstitial nephritis. Journal Immunol 1995;155:4084-9.